Literature DB >> 3005222

In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.

A L Barry, R N Jones, R R Packer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3005222     DOI： 10.1093/jac/17.1.125

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  5 in total

1.  Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

2.  In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.

Authors:  R N Jones; A L Barry; R R Packer; W W Gregory; C Thornsberry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

3.  Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.

Authors:  P C Appelbaum; M R Jacobs; S K Spangler; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

Review 4.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

5.  In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.

Authors:  R N Jones
Journal:  Drugs       Date:  1988       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.